论文部分内容阅读
Objective:To evaluate the efficacy and safety of the irinotecan and cisplatin combination in relapsed advanced small cell lung cancer (SCLC).Methods:Eligible patients with SCLC who had progressed or relapsed after therapy were treated with cisplatin and irinotecan.The regimen consisted of irinotecan 60 mg/m2 on days 1,8,15 and cisplatin 60 mg/m2 on day 1;the plan was given every 28 days.Results:In 23 evaluable patients,responses included 5 complete remissions and 7 partial remissions (overall response rate,43.4%),6 patients had stable disease and 7 had progressive disease.Median time to progression and median survival were 4.6 and 8.3 months.The main toxicities were the hematologic toxicity,nausea and vomiting.Grade Ⅲ,Ⅳ leukopenia were seen in 15 patients (65.2%),thrombocytopenia was seen in 8 patients (34.8%);Nausea and vomiting were seen in 19 patients (82.6%);Grade Ⅲ,Ⅳ nausea and vomiting were seen in 4 patients (65.2%)and diarrhea was seen in 20 patients (87.0%).There were no treatment-related deaths.Conclusion:The combination of irinotecan and cisplatin is highly active and tolerable in patients with relapsed SCLC when it is administered as second-line treatment.